Project Grant HT94252510313
Award Date
6/15/25
Completion Date
6/14/26
Dollars Obligated
$681K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The federal Project Grant award in the amount of $925,757.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research at Wake Forest University Health Sciences (WFUHS) to selectively reduce repeat expansion RNA with small molecules to treat C9ORF72 mediated amyotrophic lateral sclerosis (ALS). The award, with a period of performance from April 1, 2025 to March 31, 2027, will enable WFUHS, a private non-profit academic...
The federal Project Grant award of $1,210,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support Mayo Clinic's research on exploring novel biomarkers for amyotrophic lateral sclerosis (ALS) using a multiomics approach. The research will utilize immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays to identify potential diagnostic and prognostic markers for ALS. The award has a performance period from...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This federal Project Grant award, with a total funding amount of $1,078,882, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced biomedical research focused on understanding the multimodal therapeutic actions of neural stem cells in amyotrophic lateral sclerosis (ALS). Key elements of the research scope include: developing a chemical engineering approach to ALS, investigating surgical intervention...
This $854,060 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) was provided to Formation Venture Engineering Foundry Inc., a for-profit biotech firm, to develop an FC-fusion protein active vaccine for the prevention and treatment of C9ORF72 ALS/FTD, a rare neurodegenerative disease. The award period is from Apr 15, 2024 to Apr 14, 2026. The Military Medical Research and Development program supports innovative biomedical research...
The federal Project Grant award for $1,979,313.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports the development of a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). The grant recipient, Sachi Bioworks, Inc., is a self-certified small disadvantaged business located in Erie, Colorado, that specializes in advanced biotechnology research and development. The funding will...
This federal Project Grant award, valued at $2,180,261.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports a Phase 1C study of Prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with Amyotrophic Lateral Sclerosis (ALS). The study, conducted by Projenx Inc. located in New York, NY, aims to advance the development of this investigational therapy for treating ALS, a progressive...
The Van Andel Research Institute was awarded a $950,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 30, 2023 to September 29, 2025 to establish the neuroprotective potential of C9ORF72 hypermethylation in repeat expansion-caused ALS. Through this award, the grantee will investigate medical solutions for the battlefield by transforming health care for service members and the...
This federal Project Grant award of $1,995,027.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of California, San Diego (UCSD) to develop therapy for C9ALS (chromosome 9 open reading frame 72-associated amyotrophic lateral sclerosis) using engineered RNA-targeting zinc finger proteins. The award, effective June 1, 2025 through May 31, 2028, will fund UCSD's specialized medical research and...